CanBridge Pharmaceuticals' PD-1/VEGF Dual Antibody Ak104 Demonstrates Promising Phase III Trial Results for First-Line Therapy in Advanced Squamous Non-Small Cell Lung Cancer - Chip

7 x 24 Track global technological trends

Hot Topic

Day

News Topic

CanBridge Pharmaceuticals' PD-1/VEGF Dual Antibody Ak104 Demonstrates Promising Phase III Trial Results for First-Line Therapy in Advanced Squamous Non-Small Cell Lung Cancer

2025-04-24 / Read about 0 minute

Author：小编

CanBridge Pharmaceuticals' PD-1/VEGF dual antibody, Ak104, has yielded remarkable positive outcomes in a Phase III clinical trial for the first-line treatment of advanced squamous non-small cell lung cancer. When compared to the combination of tislelizumab and chemotherapy, the Ak104 plus chemotherapy regimen exhibited a superior progression-free survival rate, while maintaining a comparable safety profile to existing therapeutic approaches.

Previous page：Lithium Mining Stocks Surge at Market Open, Tianqi...

Next page：BOE Unveils Industry-Leading Sustainable Developme...

Return to List

Hot Reading

1 day ago

GM agrees to pay $12.75M in California driver privacy settlement

2 day ago

Cloudflare says AI made 1,100 jobs obsolete, even as revenue hit a record high

2 day ago

Missed out on the Steam Controller? Here are 5 PC and Steam-ready alternatives I've tested and recommend

2 day ago

Xbox Project Helix plans could be "shared" in just weeks – this summer's Xbox Games Showcase just became essential